Accessibility Menu
Propanc Biopharma logo

Propanc Biopharma(NASDAQ) PPCB

Current Price$1.47
Market Cap$5.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)-100%
5 Year-100%
1 Year-99%
1 Month-3%
Propanc Biopharma last closing stock price
MetricPriceDate
Last closeUSD 1.442026-07-22
Propanc Biopharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-11.66%USD 1.632026-07-15
1 month-2.7%USD 1.482026-06-22
3 month-50.34%USD 2.902026-04-23
Year to date-89.27%USD 13.422025-12-31
1 year-98.71%USD 112.002025-07-22
3 year-100%USD 165,075.002023-07-21
5 year-100%USD 65,850,000.002021-07-23
Since inception-100%USD 190,000,000.002012-11-12

Propanc Biopharma Financials at a Glance

Market Cap

$5.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$18.36M

EPS (TTM)

-$33.19

P/E Ratio

-0.04

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$1.47

Volume

22,394.602

Open

$1.44

Previous Close

$1.44

Daily Range

$1.43 - $1.53

52-Week Range

$1.30 - $270.25

Estimated Earnings Date

May 14, 2026

PPCB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Propanc Biopharma

Propanc Biopharma develops new cancer treatments for hard-to-treat cancers. Its main product aims to help patients with pancreatic, ovarian, and colorectal cancer. The company focuses on early-stage research, not selling products yet.

What’s Cooking in the Lab?

  • PRP (pro-enzyme formulation): Experimental drug designed to slow cancer growth; targets patients with pancreatic, ovarian, and colorectal cancer. 0% of revenue, as no sales yet.
  • POP1 joint drug discovery: Research partnership with University of Jaén to find new cancer therapies. 0% of revenue.
  • Intellectual property portfolio: Holds 84 patents for proenzyme use in cancer treatment; no direct revenue contribution.

Growth and Expansion: The Road So Far

  • Formed research partnership with University of Jaén in 2022 for new drug discovery.
  • Established UK subsidiary to pursue orphan drug status with European regulators.
  • Received Canadian patent for proenzyme composition in 2024, expanding North American coverage.
  • Completed 1:60,000 reverse stock split in January 2025 to support Nasdaq uplisting plans.
  • Filed S-1 registration in 2024 for proposed public offering and stock market move.

What Makes Propanc Biopharma Stand Out?

The company focuses on non-toxic cancer therapies using enzyme-based science. It holds broad patent coverage in key markets. Academic partnerships support its research into hard-to-treat cancers.

Five Things You Need to Know

  • No revenue reported for Q3 2025, Q3 2024, or Q3 2023.
  • Net loss was $54.85 million for nine months ended March 2025, up 3653% from 2024.
  • Operating expenses were $53.13 million in Q3 2025, up 12,523.7% from Q3 2024.
  • Net cash used in operating activities was $377,982 for the nine months ended March 31, 2025, an improvement of 44% compared to $675,152 for the same period in 2024.

Bottom Line

Propanc Biopharma remains a research-focused company with no commercial products. Its future depends on continued funding and successful drug development.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

2

CEO

James Andrew Nathanielsz

Website

www.propanc.com

Headquarters

Camberwell, VIC 3124, AU

PPCB Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-148.23%

Return on Capital

-366.39%

Return on Assets

-128.10%

Earnings Yield

-25.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.50M

Volume

22.39K

Avg. Volume

3.90M

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$18.37M

EBITDA

-$17.68M

Operating Cash Flow

-$4.11M

Capital Expenditure

$3.15

Free Cash Flow

-$4.11M

Cash & ST Invst.

$443.70K

Total Debt

$1.57M

Propanc Biopharma Performance Analysis

Propanc Biopharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30USD 0N/A
20232023-06-30USD 0N/A
20242024-06-30USD 0N/A
20252025-06-30USD 0N/A
Propanc Biopharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-30N/A
Q12025-09-30N/A
Q22025-12-31N/A
Q32026-03-31N/A
Propanc Biopharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30USD -73,830,233.95N/A
20232023-06-30USD -2,696,865.63-96.3%
20242024-06-30USD -35,512.90-98.7%
20252025-06-30USD -371.22-99.0%
Propanc Biopharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-3097.2%
Q12025-09-30-11.4%
Q22025-12-3123.1%
Q32026-03-316.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$5.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.52M

N/A

Employees

2

N/A

Net Income

-$6.36M

+88.2%

EBITDA

-$6.32M

+88.3%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

$443.70K

+774.1%

Total Debt

$1.57M

+26.2%

Accounts Receivable

$11.06K

+204.3%

Inventory

$0.00

N/A

Long Term Debt

$1.03M

+997.0%

Short Term Debt

$543.61K

-52.9%

Return on Assets

-1.28%

N/A

Return on Invested Capital

-1.69%

N/A

Free Cash Flow

-$1.14M

-605.8%

Operating Cash Flow

-$1.14M

-608.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ZHCLFZenith Capital Corp.
$0.05+0.00%
PRVCFPreveCeutical Medical Inc.
$0.01+0.00%
SRBCFSirona Biochem Corp.
$0.01+0.00%
SYGGFSynairgen plc
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.88-0.28%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$43.16+0.05%
HBANHuntington Bancshares
$17.38-0.05%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$37.03+0.08%

Questions About PPCB

What is the current price of Propanc Biopharma?

Propanc Biopharma is trading at $1.48 per share.

What is the 52-week range for Propanc Biopharma?

Over the past 52 weeks, Propanc Biopharma has traded between $1.30 and $270.25.

How much debt does Propanc Biopharma have?

As of the most recent reporting period, Propanc Biopharma reported total debt of $1.57M.

How much cash does Propanc Biopharma have on hand?

Propanc Biopharma reported $443.70K in cash and cash equivalents in its most recent financial results.

What is Propanc Biopharma’s dividend yield?

Propanc Biopharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services